# Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer

> **NCT07640932** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 69 (estimated)

## Conditions studied

- Carcinoma, Small Cell Lung

## Interventions

- **DRUG:** Lurbinectedin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07640932
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2027-04
- **Final completion:** 2029-02
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640932, "Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*